Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Debt to Equity (2016 - 2025)

Ironwood Pharmaceuticals' Debt to Equity history spans 12 years, with the latest figure at -$2.23 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 74.78% year-over-year to -$2.23; the TTM value through Dec 2025 reached -$2.23, down 74.78%, while the annual FY2025 figure was -$2.23, 74.78% down from the prior year.
  • Debt to Equity for Q4 2025 was -$2.23 at Ironwood Pharmaceuticals, down from -$2.21 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.37 in Q4 2023 and bottomed at -$2.23 in Q4 2025.
  • The 5-year median for Debt to Equity is -$1.28 (2024), against an average of -$1.0.
  • The largest YoY upside for Debt to Equity was 23.53% in 2024 against a maximum downside of 446.6% in 2024.
  • A 5-year view of Debt to Equity shows it stood at $0.19 in 2021, then increased by 20.75% to $0.23 in 2022, then soared by 58.29% to $0.37 in 2023, then tumbled by 446.6% to -$1.28 in 2024, then tumbled by 74.78% to -$2.23 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Debt to Equity are -$2.23 (Q4 2025), -$2.21 (Q3 2025), and -$1.9 (Q2 2025).